Success Metrics

Active Trials
2(100%)

Phase Distribution

Ph not_applicable
1
50%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

recruiting150%
active_not_recruiting150%

Recent Activity

2 active trials
Showing 2 of 2
active_not_recruitingnot_applicable

Contribution of Residual Tumour DNA Testing on the Surgical Bed

NCT05934929
recruiting

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

NCT05598528

Clinical Trials (2)

Showing 2 of 2 trials
NCT05934929Not Applicable

Contribution of Residual Tumour DNA Testing on the Surgical Bed

Active Not Recruiting
NCT05598528

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
2